How do medical device manufacturers' websites frame the value of health innovation? An empirical ethics analysis of five Canadian innovations

Medicine, Health Care and Philosophy

Volumn 15, Issue 1, 2012, Pages 61-77

  Lehoux, P ^a   Hivon, M ^a   Williams Jones, B ^a   Miller, F A ^b   Urbach, D R ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Empirical ethics; Health technology; Medical device industry; Socio technical features; Value proposition; Website analysis

Indexed keywords

ARTICLE; BIRTH INJURY; BREAST TUMOR; CANADA; CRYOSURGERY; DECISION SUPPORT SYSTEM; DEVICES; ETHICS; FEMALE; HEALTH CARE COST; HOME CARE; HUMAN; INTERNET; MASS COMMUNICATION; METHODOLOGY; MINIMALLY INVASIVE SURGERY; MOLECULAR IMAGING; MONITORING; ORTHOPEDIC SURGERY; SOCIAL PSYCHOLOGY; STATISTICS;

BIRTH INJURIES; BREAST NEOPLASMS; CANADA; CRYOSURGERY; DECISION SUPPORT SYSTEMS, CLINICAL; DIFFUSION OF INNOVATION; EQUIPMENT AND SUPPLIES; FEMALE; HEALTH CARE SECTOR; HOME CARE SERVICES; HUMANS; INTERNET; MOLECULAR IMAGING; MONITORING, PHYSIOLOGIC; ORTHOPEDIC PROCEDURES; SOCIAL VALUES; SURGICAL PROCEDURES, MINIMALLY INVASIVE;

EID: 84855960797     PISSN: 13867423     EISSN: 15728633     Source Type: Journal    
DOI: 10.1007/s11019-011-9312-5     Document Type: Article

References (37)

1. Akrich, M. 1995. User representations: Practices, methods and sociology. In Managing technology in society: The approach of constructive technology assessment, ed. A. Rip, T. J. Misa, and J. Schot, 205-224. London: Pinter.
2. Boenink, M. 2010. Molecular medicine and concepts of disease: the ethical value of a conceptual analysis of emerging biomedical technologies. Medicine, Health Care and Philosophy 13: 11-23.
3. Boltanski, L., and L. Thévenot. 1991. De la justification. Les économies de la grandeur. Paris: Gallimard.
4. Brown, N. 2003. Hope against hype-accountability in biopasts, presents and futures. Science Studies 162: 3-21.
5. Brown, N., and A. Webster. 2004. New medical technologies and society: Reordering life. Cambridge: Polity Press.
6. Chesbrough, H., and R. S. Rosenbloom. 2002. The role of the business model in capturing value from innovation: evidence from Xerox Corporation's technology spin-off companies. Industrial and Corporate Change 11(3): 529-555.
7. de Chernatony, L., F. Harris, and F. D. Riley. 2000. Added value: its nature, roles and sustainability. European Journal of Marketing 34(1/2): 39-56.
8. Einsiedel, E. F. 2006. Introduction: Making sense of emerging technologies. In: First Impressions: Understanding Public Views on Emerging Technologies. GenomePrairie GE3LS Team, University of Calgary.
9. Evans, B. 1984. Strained mercy: The economics of Canadian health care. Toronto, Canada: Butterworths.
10. Faulkner, A. 2008. Medical technology into healthcare and society: A sociology of devices, innovation and governance. Hampshire, UK: Palgrave Macmillan.
11. Faulkner, A., and J. Kent. 2001. Innovation and regulation in human implant technologies: developing comparative approaches. Social Science and Medicine 53(7): 895-913.
12. Gagnon, M.-A. and J. Lexchin. 2008. The Cost of Pushing Pills: A new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med 5(1): e1. doi: 10. 1371/journal. pmed. 0050001.
13. Gagnon, M.-A. 2009. The nature of capital in the knowledge-based economy: The case of the global pharmaceutical industry. York University: PhD in Political Science Dissertation.
14. Giacomini, M., J. Hurley, I. Gold, P. Smith, and J. Abelson. 2004. The policy analysis of value talk: Lessons from Canadian Health reform. Health Policy 67: 15-24.
15. Grunwald, A. 2004. The normative basis of health technology assessment and the role of ethical expertise. Poiesis & Praxis 2: 175-194.
16. Haimes, E. 2002. What can the social sciences contribute to the study of ethics? Theoretical, empirical and substantive considerations. Bioethics 16(2): 89-113.
17. Häyry, M. 2003. European values in bioethics: Why, what, and how to be used? Theoretical Medicine 24: 199-214.
18. Hemminki, E., H. K. Toiviainen, and L. Vuorenkoski. 2010. Co-operation between patient organisations and the drug industry in Finland. Social Science and Medicine 70(8): 1171-1175.
19. Jasanoff, S. 2005. Design on Nature: Science and Democracy in Europe and the United States. Princeton, NJ: Princeton University Press.
20. Lake, C. C., R. A. Crittendon, and D. Mermin. 2008. Health care in the 2008 election: Engaging the voters. Health Affairs 27(3): 693-708.
21. Lehoux, P. 2006. The problem of health technology. Policy implications for modern health care systems. New York: Routledge.
22. Lehoux, P., J.-L. Denis, M. Rock, S. Tailliez, and M. Hivon. 2009. How do medical specialists appraise three controversial health innovations? Scientific, clinical and social arguments. Sociology of Health & Illness 32(1): 1-17.
23. Light, D. W., R. Castellblanch, P. Arredondo, and D. Socolar. 2003. No exit and the organization of voice in biotechnology and pharmaceuticals. Journal of Health Politics, Policy and Law 2(2-3): 473-507.
24. Molewijk, A. C., A. M. Stiggelbout, W. Otten, H. M. Dupuis, and J. Kievit. 2004. Implicit normativity in evidence-based medicine: A plea for integrated empirical ethics research. Health Care Analysis 11: 69-92.
25. Nelson, G. D. 1995. Medical device industry efforts to increase healthcare value. The Annals of Thoracic Surgery 60: 1534-1536.
26. Normann, R., and R. Ramirez. 1994. Designing Interactive Strategy: From Value Chain to Value Constellation. Chichester: John Wiley & Sons.
27. Porter, M. 1985. Competitive Strategy. Techniques for Analysing Industries and Competitors. New York: The Free Press.
28. Priester, R. 1992. A values framework for health system reform. Health Affairs 11(1): 84-107.
29. Ramirez, R. 1999. Value co-production: intellectual origins and implications for practice and research. Strategic Management Journal 20: 49-65.
30. Saukko, P. M., M. Reed, N. Britten, and S. Hogarth. 2010. Negotiating the boundary between medicine and consumer culture: Online marketing of nutrigenetic tests. Social Science and Medicine 70: 744-753.
31. Smith, E., C. Martin, J. Behrmann, and B. Williams-Jones. 2010. Reproductive tourism in Argentina: accreditation and its implications for consumers and policy makers. Developing World Bioethics 10(2): 59-69. (Published Online First: June 8 2009).
32. Strauss, A., and J. Corbin. 1990. Basics of Qualitative Research. Newbury Park: Sage.
33. Teutsch, S. M., and M. L. Berger. 2005. Misaligned incentives in Americas health: Who's minding the store? Annals of Family Medicine 3(6): 485-487.
34. Vicente, K. 2004. The Human Factor: Revolutionizing the Way People Live with Technology. New York: Routledge.
35. Williams-Jones, B., and O. P. Corrigan. 2003. Rhetoric and hype: Where's the "Ethics" in pharmacogenomics? American Journal of Pharmacogenomics 36: 375-383.
36. Williams-Jones, B. 2006. Be ready against cancer, now: Direct-to-consumer advertising for genetic testing. New Genetics and Society 25(1): 89-107.
37. Woolf, S. H., and R. E. Johnson. 2005. The break-even point: When medical advances are less important than improving the fidelity with which they are delivered. Annals of Family Medicine 3(6): 545-552.